Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says

Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says
Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase 3 clinical trial shows. It also improved several other patient outcomes, extending the time to a new cancer treatment and to worsening of pain, stretching the time to resistance to ADT, and reducing the likelihood of bone symptoms — all without added side effects or worsening quality of life. The results were published in the Journal of Clinical Oncology in a paper titled, "ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer." ADT aims to reduce the amounts of active androgens, the so-called "male hormones" that can drive the growth of some prostate tumors. These cancers are thus referred to as "hormone-sensitive." Xtandi, developed by Pfizer and Astellas, works in a slightly different way, but toward the same end. The treatment blocks receptors for androgens, preventing them from sending signals to cancer cells. Researchers questioned if these two therapies might control hormone-sensitive prostate cancers best if the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *